Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant alectinib versus platinum-based chemotherapy after complete resection for ALK-positive non-small cell lung cancer
jRCT2080224014Phase 4Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 4, randomised, open-label trial of alectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Aug 2018; status: completed.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224014.